DXCM · DexCom, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on DXCM. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About DXCM · DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Live Quote
HOLD (score +0) · 12-1 mom -17.9% · RSI 44.8 · above_both · -23.0% from high
Targets blend Wall Street consensus (24 analysts: low $65.00 / mean $85.21 / high $112.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage produced output that could not be parsed as a valid JSON object. ~6h cooldown before retry.
{"symbol":"DXCM","company":"DexCom, Inc.","investigation_summary":"The trigger — 4 Form 4s in 14 days with a verified P/S trade — was investigated by reading every filing. The cluster consisted entirely of routine RSU vestings (code A), tax withholding sells (F), and trust re-registrations (G) — NO open-market purchases by any named executive or director in the past 90 days. The Q1 2026 beat (+19%